Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

NCT05292586 · View on ClinicalTrials.gov ↗

Study Summary

Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.

Conditions Studied

Interventions

  • DRUG Beclomethasone Dipropionate/Formoterol Fumarate
  • DRUG Beclomethasone Dipropionate

Study Locations (20)

California

  • Chiesi Clinical Trial Site 840856 — Encinitas
  • Chiesi Clinical Trial Site 840843 — Huntington Beach
  • Chiesi Clinical Trial Site 840860 — Huntington Beach
  • Chiesi Clinical Trial Site 840896 — Long Beach
  • Chiesi Clinical Trial Site 840883 — Los Angeles
  • Chiesi Clinical Trial Site 840810 — Los Angeles
  • Chiesi Clinical Trial Site 840869 — Newport Beach
  • Chiesi Clinical Trial Site 840890 — North Hollywood
  • Chiesi Clinical Trial Site 840808 — Northridge
  • Chiesi Clinical Trial Site 840879 — Pomona
  • Chiesi Clinical Trial Site 840868 — Sacramento
  • Chiesi Clinical Trial Site 840849 — San Diego
  • Chiesi Clinical Trial Site 840877 — San Diego
  • Chiesi Clinical Trial Site 840861 — San Jose
  • Chiesi Clinical Trial Site 840881 — Westminster

Colorado

  • Chiesi Clinical Trial Site 840873 — Colorado Springs
  • Chiesi Clinical Trial Site 840800 — Denver

Alabama

  • Chiesi Clinical Trial Site 840858 — Mobile

Arizona

  • Chiesi Clinical Trial Site 840895 — Chandler

Florida

  • Chiesi Clinical Trial Site 840820 — Coral Gables

Trial Details

FieldValue
Enrollment Target 1,377 participants
Start Date 2022-08-31
Est. Completion 2024-06-24
Phase Phase 3

Sponsor

Chiesi Farmaceutici S.p.A.

7 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05292586

The ClinicalTrials.gov registry entry for NCT05292586 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions — of which Beclomethasone Dipropionate/Formoterol Fumarate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05292586 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Colorado, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05292586 about?

NCT05292586 is a clinical study titled "A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid". Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.

What is the current status of trial NCT05292586?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,377 participants. The study started on 2022-08-31. Estimated completion is 2024-06-24.

What conditions does trial NCT05292586 study?

This clinical trial studies the following conditions: Asthma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05292586?

The interventions under investigation include: Beclomethasone Dipropionate/Formoterol Fumarate (DRUG), Beclomethasone Dipropionate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05292586?

This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05292586 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial